"Jan. 23, 2013 -- Worrying about what may trigger a migraine attack adds to the discomfort of many people with migraines. But according to a new study from Denmark, much of that worry may be unfounded.
The researchers studied the effect of l"...
- Patient Information:
Details with Side Effects
Signs and Symptoms
Patients and volunteers receiving single oral doses of 100 to 150 mg of almotriptan did not experience significant adverse events. Six additional normal volunteers received single oral doses of 200 mg without serious adverse events. During clinical trials with AXERT (almotriptan malate) , one patient ingested 62.5 mg in a 5-hour period and another patient ingested 100 mg in a 38-hour period. Neither patient experienced adverse reactions.
Gastrointestinal decontamination (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with AXERT (almotriptan malate) . Clinical and electrocardiographic monitoring should be continued for at least 20 hours, even if clinical symptoms are not observed.
Ischemic or Vasospastic Coronary Artery Disease or other Significant Underlying Cardiovascular Disease
Do not use AXERT (almotriptan malate) in patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or in patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease [see WARNINGS AND PRECAUTIONS].
Do not use AXERT (almotriptan malate) in patients with cerebrovascular syndromes including (but not limited to) stroke of any type as well as transient ischemic attacks [see WARNINGS AND PRECAUTIONS].
Peripheral Vascular Disease
Ergotamine-Containing and Ergot-Type Medications
Do not use AXERT (almotriptan malate) and ergotamine-containing or ergot-derived medications like dihydroergotamine, ergotamine tartrate or methysergide within 24 hours of each other [see DRUG INTERACTIONS].
Concomitant Use With 5-HT1 Agonists (e.g. Triptans)
AXERT (almotriptan malate) and other 5-HT1 agonists (e.g. triptans) should not be administered within 24 hours of each other [see WARNINGS AND PRECAUTIONS].
Hemiplegic or Basilar Migraine
Do not use AXERT (almotriptan malate) in patients with hemiplegic or basilar migraine.
AXERT (almotriptan malate) is contraindicated in patients with known hypersensitivity to almotriptan or any of its inactive ingredients.
Last reviewed on RxList: 5/29/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Axert Information
Axert - User Reviews
Axert User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find the secrets to longer life.